These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22864966)

  • 21. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Seeman P; Tallerico T
    Mol Psychiatry; 1998 Mar; 3(2):123-34. PubMed ID: 9577836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.
    Quednow BB; Wagner M; Westheide J; Beckmann K; Bliesener N; Maier W; Kühn KU
    Biol Psychiatry; 2006 Mar; 59(6):536-45. PubMed ID: 16139819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
    Takaki M; Ujike H
    Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amisulpride improved debilitating clozapine-induced sialorrhea.
    Praharaj SK; Ray P; Gandotra S
    Am J Ther; 2011 May; 18(3):e84-5. PubMed ID: 20068443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label trial of risperidone augmentation for refractory anxiety disorders.
    Simon NM; Hoge EA; Fischmann D; Worthington JJ; Christian KM; Kinrys G; Pollack MH
    J Clin Psychiatry; 2006 Mar; 67(3):381-5. PubMed ID: 16649823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chorea].
    Vieregge P
    Ther Umsch; 2007 Jan; 64(1):54-6. PubMed ID: 17221825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
    Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Possibilities in using sulpiride in the treatment of psychotic disorders].
    Danilov DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(6):91-7. PubMed ID: 22983256
    [No Abstract]   [Full Text] [Related]  

  • 31. Sulpiride plus hydroxyzine decrease tinnitus perception.
    Lopez-Gonzalez MA; Moliner-Peiro F; Alfaro-Garcia J; Esteban-Ortega F
    Auris Nasus Larynx; 2007 Mar; 34(1):23-7. PubMed ID: 17118597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
    Düring S; Glenthøj BY; Oranje B
    Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
    Kang SG; Na KS; Lee HJ; Chee IS; Lee K; Lee J
    J Clin Psychopharmacol; 2015 Apr; 35(2):158-62. PubMed ID: 25679126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The response to sulpiride in social anxiety disorder: D2 receptor function.
    Bell C; Bhikha S; Colhoun H; Carter F; Frampton C; Porter R
    J Psychopharmacol; 2013 Feb; 27(2):146-51. PubMed ID: 22745189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine D2/3 receptor antagonism reduces activity-based anorexia.
    Klenotich SJ; Ho EV; McMurray MS; Server CH; Dulawa SC
    Transl Psychiatry; 2015 Aug; 5(8):e613. PubMed ID: 26241351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Betamax (sulpirid): potential for clinical application].
    Ivanov SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):83-7. PubMed ID: 22433816
    [No Abstract]   [Full Text] [Related]  

  • 39. Anxiolytic-like effect of quinpirole in combination with a low dose of 17β-estradiol in ovariectomized rats.
    Fedotova J
    Acta Physiol Hung; 2013 Jun; 100(2):211-23. PubMed ID: 23708948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D4 receptors: a new opportunity for research on schizophrenia.
    Liégeois J; Eyrolles L; Bruhwyler J; Delarge J
    Curr Med Chem; 1998 Apr; 5(2):77-100. PubMed ID: 9481035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.